Ethypharm in licensing deal with Shantha Biotechnics

Mumbai: French pharmaceutical company Ethypharm has entered into a licensing and supply agreement with Hyderabad-based Shantha Biotechnics for marketing an anti-nausea drug in India.

As per the agreement, Ethypharma would supply Ondansetron from its manufacturing facility near Mumbai, which would be marketed and distributed by Shantha Biotechnics in India , Ethypharm said in a statement.

Ondansetron is used to prevent nausea and vomiting associated with chemotherapy, certain radiotherapies, and the prevention of postoperative nausea or vomiting.

Patients who have difficulty with swallowing or who are not able to drink use Ondansetron Flashtab.

"Introduction of Ondansetron Flashtab showcases our strength in developing innovative solutions in the fast growing NDDS segment," Ajey Kumar, chief executive, Ethypharm India, said in the statement.

Indian companies are increasingly exploring alliances to enlarge their market. Shantha Biotechnics with assistance from the Centre for Cellular and Molecular Biology, launched India's first recombinant vaccine for Hepatitis B called Shanvac in 1997.